Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
A Marra, D Trapani, G Viale, C Criscitiello… - NPJ breast …, 2020 - nature.com
Triple-negative breast cancer (TNBC) is not a unique disease, encompassing multiple
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …
[HTML][HTML] HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer
EC de Heer, M Jalving, AL Harris - The Journal of clinical …, 2020 - Am Soc Clin Investig
Hypoxia-inducible factors (HIFs) and the HIF-dependent cancer hallmarks angiogenesis and
metabolic rewiring are well-established drivers of breast cancer aggressiveness, therapy …
metabolic rewiring are well-established drivers of breast cancer aggressiveness, therapy …
[HTML][HTML] Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
Background Previous trials showed that antiangiogenesis or anti-programmed death protein
1/programmed death ligand 1 (PD-1/PD-L1) monotherapy only showed marginal effect in …
1/programmed death ligand 1 (PD-1/PD-L1) monotherapy only showed marginal effect in …
Silencing of VEGFR2 by RGD-modified lipid nanoparticles enhanced the efficacy of anti-PD-1 antibody by accelerating vascular normalization and infiltration of T cells …
R Cho, Y Sakurai, HS Jones, H Akita, A Hisaka… - Cancers, 2020 - mdpi.com
Simple Summary siRNA delivery to tumor endothelial cells was achieved using arginyl-
glycyl-aspartic acid (RGD)-modified lipid nanoparticles containing a novel pH-sensitive and …
glycyl-aspartic acid (RGD)-modified lipid nanoparticles containing a novel pH-sensitive and …
Probing the effects of the FGFR-inhibitor derazantinib on vascular development in Zebrafish embryos
MP Kotini, F Bachmann, J Spickermann… - Pharmaceuticals, 2020 - mdpi.com
Angiogenesis is a fundamental developmental process and a hallmark of cancer
progression. Receptor tyrosine kinases (RTK) are targets for cancer therapy which may …
progression. Receptor tyrosine kinases (RTK) are targets for cancer therapy which may …